

Pembrolizumab

Indication

- Metastatic or unresectable stage 3 and stage 4 melanoma
- Adjuvant treatment of adults with stage 2b, 2c and 3 melanoma who have undergone complete resection
- 1st line treatment of metastatic non-small cell lung cancer (NSCLC) in patients whose tumours express PD-L1 with a $\geq 50\%$ tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations
- In combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment for the treatment of resectable NSCLC at high risk of recurrence in adults (prescribe chemotherapy separately)
- Adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy
- Locally advanced or metastatic PD-L1 positive ($\geq 1\%$ PD-L1 expression) NSCLC in patients who have had at least one previous chemotherapy
- Relapsed or refractory classical Hodgkin lymphoma (cHL) in patients who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV
- Relapsed or refractory classical Hodgkin lymphoma (cHL) in patients who are currently ineligible for stem cell transplantation and who have not received brentuximab vedotin
- 1st line treatment of PD-L1 positive metastatic or unresectable recurrent squamous cell carcinoma of the head and neck
- 1st line treatment of patients with metastatic colorectal cancer exhibiting microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR)
- Adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
- Tumours with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency in adults with:
 - advanced or recurrent endometrial cancer that has progressed during or after a platinum-based therapy, who cannot have curative surgery or radiotherapy
 - unresectable or metastatic gastric, small intestine or biliary cancer that has progressed during or after 1 therapy
 - colorectal cancer after fluoropyrimidine combination therapy, only if they cannot have nivolumab with ipilimumab

ICD-10 codes

Dependant on tumour site.

Regimen details

Day	Drug	Dose	Route
1	Pembrolizumab	200mg every 3 weeks or 400mg every 6 weeks	IV infusion

Cycle frequency

21 days or 42 days as above

Number of cycles

Melanoma (metastatic) and Renal Cell Carcinoma

Until unacceptable toxicity, disease progression or consultant discretion (sustained complete response).

Melanoma (adjuvant)

Adjuvant treatment should continue for 12 months (18 cycles of 200mg or 9 cycles of 400mg) or until disease progression, withdrawal of consent, or unacceptable toxicity.

Renal Cell Carcinoma (adjuvant)

Adjuvant treatment should continue for 17 cycles of 200mg or 9 cycles of 400mg

Resectable NSCLC

In combination with chemotherapy for 4 doses every 3 weeks or 2 doses every 6 weeks; followed by adjuvant treatment as monotherapy for 13 doses of 200mg every 3 weeks or 7 doses of 400mg every 6 weeks

NSCLC adjuvant following complete resection and platinum-based chemotherapy

Adjuvant treatment should continue for 17 cycles of 3-weekly or 9 cycles of 6-weekly or until disease progression, withdrawal of consent or unacceptable toxicity

Other indications

Until unacceptable toxicity, disease progression or consultant discretion (sustained complete response). Treatment should stop at 2 years.

Administration

Pembrolizumab should be administered in 100mL sodium chloride 0.9% over 30 minutes.

Pembrolizumab should be administered via an infusion set with an in-line sterile, non-pyrogenic, low protein binding filter (pore size 0.2 – 5.0µm).

After the infusion the line should be flushed with 30mL sodium chloride 0.9%.

Patients should be monitored every 30 minutes during the infusion (blood pressure, pulse and temperature) and for infusion related reactions. For mild to moderate reactions, decrease the infusion rate and closely monitor.

Premedication with paracetamol and chlorphenamine should be used for further doses. For severe infusion related reactions discontinue treatment.

Pre-medication

Nil

Emetogenicity

This regimen has low emetogenic potential

Additional supportive medication

Antiemetics as per local policy, if required.

Extravasation

Neutral (Group 1)

Investigations – pre first cycle

Standard pre-SACT tests as per network policy

PD-L1 tumour expression if required for some indications, please refer to list above.

Investigations – pre subsequent cycles

Investigation	Validity period (or as per local policy)
FBC	48 hours
U+E (including creatinine)	48 hours
LFT inc AST	48 hours
LDH (melanoma only)	48 hours
Thyroid function	Every 6 weeks unless otherwise clinically indicated
Glucose	As clinically indicated
Calcium	As clinically indicated
Cortisol	At consultant discretion

Standard limits for administration to go ahead

If blood results not within range, authorisation to administer **must** be given by prescriber/ consultant.

Investigation	Limit
Neutrophil count	$\geq 1.0 \times 10^9/L$
Platelets	$\geq 75 \times 10^9/L$
Creatinine Clearance (CrCl)	$\geq 30\text{mL/min}$
Bilirubin	Serum total bilirubin $\leq 1.5 \times \text{ULN}$ or direct bilirubin $\leq \text{ULN}$ for patient with total bilirubin level $>1.5 \text{ ULN}$
ALT/AST	$\leq 2.5 \times \text{ULN}$ or $\leq 5 \times \text{ULN}$ with liver metastases
Alkaline Phosphatase	$< 5 \times \text{ULN}$

Dose modifications

Do not amend the dose of pembrolizumab

Consider immunotherapy driven toxicity as a potential reason for all changing laboratory results and discuss with a consultant if any concerns.

- **Haematological toxicity**

Discuss with the consultant if:

Neutrophils $< 1.0 \times 10^9/L$

Platelets $< 75 \times 10^9/L$

- **Renal impairment/toxicity**

The safety and efficacy of pembrolizumab has not been studied in patients with renal impairment. No specific dose adjustments are recommended in mild to moderate renal impairment.

Discuss with consultant if CrCl $< 30\text{mL/min}$.

- **Hepatic impairment/toxicity**

The safety and efficacy of pembrolizumab has not been studied in patients with hepatic impairment. No specific dose adjustments are recommended in mild hepatic impairment. See below for management of hepatitis.

- **Endocrine toxicity**

Dose delays are not routinely required for abnormalities in endocrine function. Please seek advice from patient's treating clinician.

- **Other toxicities**

Patients must be advised to seek specialist advice if they experience side effects as these can worsen rapidly.

Immune reactions may occur during or after completion of treatment.

Treatment of toxicities

Immunotherapy toxicities should be aggressively managed as can cause permanent and life-threatening complications.

Refer to UKONS and ESMO guidance for treatment of immune related toxicities.

Available at:

https://www.healthierlsc.co.uk/application/files/7916/8977/4069/UKONS_AO_initial_management_Guidelines_FINAL_VERSION_2023.pdf

https://www.healthierlsc.co.uk/application/files/8916/8744/0377/ESMO_IO_Toxicity_Treatment_Guidance.pdf

- **Toxicity monitoring and dose delays/discontinuation.**

All toxicities should be actively management and monitored. Any dose delays or discontinuation should be supervised by the treating clinician and made on an individual patient basis.

Adverse effects - for full details consult product literature/ reference texts

- **Serious side effects**

Myelosuppression

Pneumonitis

Colitis

Hepatitis

Nephritis

Endocrinopathies

Pancreatitis

- **Frequently occurring side effects**

Myelosuppression

Reduced appetite

Headache Dizziness

Dry eyes

Cough

Diarrhoea

Nausea Rash

Fatigue

Hyperglycaemia

Hypocalcaemia

- **Other side effects**

Arthralgia

Significant drug interactions – for full details consult product literature/ reference texts

Corticosteroids: use of systemic corticosteroids at baseline, before starting pembrolizumab, should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of pembrolizumab. However, systemic corticosteroids or other immunosuppressants can be used after starting pembrolizumab to treat immune-related adverse reactions.

Additional comments

Women of child bearing potential should use effective contraception during treatment and for at least 4 months after the last dose.

References

- <http://www.swscn.org.uk/guidance-protocols/cancer-protocols/> accessed 9 Jul 2020
- National Institute for Health and Clinical Excellence TA357. Accessed 23 December 2015 via www.nice.org.uk
- National Institute for Health and Clinical Excellence TA366. Accessed 23 December 2015 via

www.nice.org.uk

- Summary of Product Characteristics Pembrolizumab via www.medicines.org.uk
 - Ribas, A et al; Pembrolizumab v investigator choice chemotherapy. Lancet 2015; 16 (8): 908 – 918
 - Robert, C et al; Pembrolizumab v Ipilimumab in advanced melanoma. NEJM 2015 ; 372 :2521 – 2532
- Choueiri et al; Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med 2021; 385:683-694

THIS PROTOCOL HAS BEEN DIRECTED BY PROF BOARD, DESIGNATED LEAD CLINICIAN FOR MELANOMA

RESPONSIBILITY FOR THIS PROTOCOL LIES WITH THE HEAD OF SERVICE

Date: December 2024

Review: December 2026

VERSION: 24